

Jubilant, Janssen expand drug discovery alliance

21 February 2014 | News | By BioSpectrum Bureau



Singapore: Jubilant Biosys, a subsidiary of Bangalore-based Jubilant Life Sciences, has expanded its drug discovery alliance with Janssen Pharmaceutica, that was forged initially in the year 2011 aims, to deliver preclinical candidates to Janssen in multiple therapeutic areas.

Belgium-based Janssen Pharmaceutica is subsidiary of Johnson & Johnson. The collaboration between the two organizations has been expanded to leverage Jubilant's drug discovery capabilities on selected drug discovery targets to advance programs in multiple disease areas.

Jubilant will carry out research services and will deliver preclinical candidates to Janssen for potential development and commercialization. In addition to research funding, Jubilant will also receive milestones and royalties should Janssen successfully progress the assets into clinical development and commercialization.

"We are pleased to announce the expansion of the Janssen- Jubilant collaboration and look forward to discovering Novel Chemical Entities (NCE's) that address the unmet medical needs in these important disease areas", said Dr Subir K Basak, president, Jubilant Biosys' Global Drug Discovery Services.

"Over the past several years, we have been strengthening our disease franchises from a scientific perspective, and this collaboration serves as a validation of those efforts. We look forward to a long, and mutually beneficial, partnership," he added.